Category: Press Releases

Posted on

Sabin Vaccine Institute Begins Phase 2 Clinical Trial for Marburg Vaccine in Uganda

Clinical Trial Preparation
Staff at Makerere University Walter Reed Project preparing for Sabin’s Phase 2 Marburg vaccine clinical trial.

Staff at Makerere University Walter Reed Project preparing for Sabin’s Phase 2 Marburg vaccine clinical trial.

WASHINGTON, Oct. 19, 2023 (GLOBE NEWSWIRE) — The Sabin Vaccine Institute has launched a Phase 2 clinical trial for its vaccine candidate against the lethal Marburg virus. Healthy volunteers received the single-dose vaccine at Makerere University Walter Reed Project (MUWRP) in Kampala, Uganda today.

There are currently no vaccines or antiviral treatments approved to treat Marburg virus disease. Marburg is a filovirus, in the same family as the virus that causes Ebola. Like Ebola, Marburg virus disease spreads between people via direct contact with the blood or other bodily fluids of infected people, is highly virulent, and causes hemorrhagic fever. The disease has a fatality rate of up to 88%.

Based on the ChAd3 platform, Sabin’s single-dose investigational Marburg vaccine was found to be promising in Phase 1 clinical and non-clinical studies, with results showing it to be safe, while eliciting rapid and robust immune responses.

Dr. Betty Mwesigwa, deputy executive director of MUWRP, is the principal investigator for the Kampala portion of the Sabin-sponsored trial. Participants will also be enrolled a few weeks later at a second site at the Kenya Medical Research Institute in Siaya, Kenya, with Dr. Videlis Nduba as principal investigator. In all, 125 volunteers will participate in the trial.

“We have an extraordinary opportunity here to improve our preparedness to save lives and protect people from a deadly and unforgiving disease that typically strikes under-resourced countries first and most,” says Amy Finan, Sabin’s Chief Executive Officer. “Sabin’s Phase 2 clinical trial builds on a solid safety and immunogenicity foundation and we are hoping it will generate the information needed to move the vaccine toward licensure.”

The number of Marburg outbreaks in Africa has climbed steadily in recent years. Two outbreaks of Marburg virus disease have occurred already this year: Equatorial Guinea reported its first ever documented Marburg outbreak, which killed 12 people, followed by Tanzania, where six people succumbed to the virus. Communities in Uganda and Kenya are familiar with Marburg virus disease, having been ravaged by outbreaks over multiple years in the last few decades.

“Makerere University Walter Reed Project (MUWRP) is delighted to partner with the Sabin Vaccine Institute to launch the clinical testing for a preventive Marburg vaccine,” says Dr. Mwesigwa. “Most Marburg virus disease outbreaks have originated in Africa. Uganda alone has registered 4 outbreaks of the disease. We urgently need a vaccine against Marburg because of its potential to cause epidemics with significant death rates. It is imperative for us to test candidate vaccines in Uganda, a country prone to these outbreaks. This work will contribute new knowledge to inform the scientific discovery for an effective vaccine against the deadly Marburg virus.”

The Phase 2 clinical trial for Sabin’s Marburg vaccine will continue to evaluate safety and immunogenicity for the vaccine, this time among a larger group of individuals. This is a randomized, placebo-controlled, double-blind study, meaning that neither the participants nor the researchers will know whether trial participants receive a vaccine dose or a placebo dose until after the trial is over, an approach used to help reduce experimental bias.

Participants in the clinical trial will be monitored for a full year and will include both younger (18-50 years) and older age groups (51-70 years). Interim results are expected next year. In addition to the current trial in Uganda and Kenya, Sabin plans to conduct a similar Phase 2 clinical trial for Marburg in the U.S.

The Marburg vaccine trials are supported by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response within the U.S. Department of Health and Human Services, under multi-year contracts between the organizations, including most recently a $36.4 million award for vaccine development and production.

Similarly, BARDA has invested in Sabin for advancing ChAd3 Sudan ebolavirus vaccine candidate, including awarding $28 million this August for Phase 2 clinical trials in the U.S.

To date, Sabin has received around $215 million in contract awards from BARDA for furthering vaccine research and development against Sudan ebolavirus and Marburg virus diseases.

BARDA and Sabin began working together in September 2019 to develop the two monovalent vaccine candidates. Sabin’s Sudan ebolavirus vaccine candidate was the first to arrive in Uganda last year during the disease outbreak that left 55 people dead. Sabin has also initiated plans for a Phase 2 Sudan ebolavirus vaccine clinical trial in Uganda and Kenya.

This project has been supported in whole or in part with federal funds from the Department of Health and Human Services; Administration for Strategic Preparedness and Response; Biomedical Advanced Research and Development Authority (BARDA), under contract numbers 75A50119C00055 and 75A50123C00010.

About the Sabin Vaccine Institute

The Sabin Vaccine Institute is a leading advocate for expanding vaccine access and uptake globally, advancing vaccine research and development, and amplifying vaccine knowledge and innovation. Unlocking the potential of vaccines through partnership, Sabin has built a robust ecosystem of funders, innovators, implementers, practitioners, policy makers and public stakeholders to advance its vision of a future free from preventable diseases. As a non-profit with three decades of experience, Sabin is committed to finding solutions that last and extending the full benefits of vaccines to all people, regardless of who they are or where they live. At Sabin, we believe in the power of vaccines to change the world. For more information, visit www.sabin.org and follow us on X, @SabinVaccine.About Sabin’s Vaccine R&D Using the ChAd3 Platform.

About Sabin’s Vaccine R&D Using the ChAd3 Platform

In August 2019, Sabin announced exclusive agreements with GSK for Sabin to advance the development of the prophylactic candidate vaccines against the deadly Ebola Zaire, Ebola Sudan and Marburg virus. The three candidate vaccines were initially developed collaboratively by the U.S. National Institutes of Health and Okairos, which was acquired by GSK in 2013. The candidate vaccines, based on GSK’s proprietary ChAd3 platform, were further developed by GSK, including the Phase II development for the Ebola Zaire vaccine. Under the agreements between GSK and Sabin, Sabin exclusively licensed the technology for all three candidate vaccines and acquired certain patent rights specific to these vaccines.

About the Makerere University Walter Reed Project

MUWRP is a non-profit biomedical research organization with a mission to mitigate disease threats through quality research, health care and disease surveillance. The project’s scope includes among others; clinical research in infectious and non-infectious diseases such as HIV, Ebola, Marburg, COVID-19, Influenza and Influenza-like illnesses, and neglected tropical diseases such as Schistosomiasis, among others. A major part of the clinical research are clinical trials, where the MUWRP has conducted more than 12 phase I and II vaccine clinical trials including the first Ebola vaccine trial in Africa.

Media Contact:
Monika Guttman
Media Relations Specialist
Sabin Vaccine Institute
+1 (202) 662-1841
press@sabin.org

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/0ecbc982-493a-4ecf-9393-e203708aa3ea

GlobeNewswire Distribution ID 8952340

Posted on

The Metals Company Provides Closing Update on its Registered Direct Offering at $2.00 Per Share Plus Class A Warrants

NEW YORK, Oct. 19, 2023 (GLOBE NEWSWIRE) — TMC the metals company Inc. (Nasdaq: TMC) (“TMC” or the “Company”), an explorer of lower-impact battery metals from seafloor polymetallic nodules, today provided an update to its previously announced registered direct offering (the “Registered Offering”), which is expected to result in aggregate gross proceeds to the Company of approximately $24.9 million, the majority of which has already been received.

Pursuant to the Registered Offering, TMC agreed to sell and issue common shares of the Company, without par value (the “Common Shares”), and accompanying Class A warrants (the “Class A Warrants”) at an exercise price per share of $3.00. Each Common Share and the accompanying Class A Warrant to purchase 0.5 of a Common Share were sold at a price of $2.00. The approximately $24.9 million of expected gross proceeds to the Company includes the two additional closings for $2.5 million and $6.5 million expected to occur on or before November 30, 2023 and January 31, 2024, respectively, with an investor in the Registered Direct Offering affiliated with the Company, and is before deducting fees payable to the financial advisors and other estimated offering expenses payable by the Company, not including exercise of the Class A Warrants.

In addition to the proceeds from the Registered Offering and cash on hand, TMC has access to a $25 million unsecured credit facility with an affiliate of Allseas Group S.A., as well as a $30 million at-the-market equity program (ATM), both of which remain unused as of today.

The securities in the Registered Offering were offered by TMC pursuant to an effective shelf registration statement that was previously filed with the U.S. Securities and Exchange Commission (“SEC”) on September 16, 2022, as amended, and declared effective by the SEC on October 14, 2022. The Registered Offering was made only by means of a written prospectus and prospectus supplement that form a part of the registration statement. A prospectus supplement dated August 14, 2023 relating to and describing the terms of the offering was filed with the SEC and is available on the SEC’s website at www.sec.gov.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.

About The Metals Company
The Metals Company is an explorer of lower-impact battery metals from seafloor polymetallic nodules, on a dual mission: (1) supply metals for the global energy transition with the least possible negative impacts on planet and people and (2) trace, recover and recycle the metals we supply to help create a metal commons that can be used in perpetuity. The Company through its subsidiaries holds exploration and commercial rights to three polymetallic nodule contract areas in the Clarion Clipperton Zone of the Pacific Ocean regulated by the International Seabed Authority and sponsored by the governments of Nauru, Kiribati and the Kingdom of Tonga. More information is available at www.metals.co.

More info
Media | media@metals.co
Investors | investors@metals.co

Forward-Looking Statements

This press release contains “forward-looking” statements and information within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as “aims,” “anticipates,” “believes,” “could,” “estimates,” “expects,” “forecasts,” “goal,” “intends,” “may,” “plans,” “possible,” “potential,” “seeks,” “will” and variations of these words or similar expressions, although not all forward-looking statements contain these words. Forward-looking statements in this press release include, but are not limited to, statements concerning: the timing, terms and size, including the expected proceeds from, of the Registered Offering and the expected additional closings in the Registered Offering. The Company may not actually achieve the plans, intentions or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various factors, including, among other things: the Company’s ability to satisfy the closing conditions in the securities purchase agreement; the risk that the investors will not exercise the warrants issued or issuable as part of the Registered Offering; the Company’s ability to access additional funds under the unsecured credit facility, the ATM or otherwise; the Company’s strategies and future financial performance; the International Seabed Authority’s (“ISA”) ability to timely adopt the Mining Code and/or willingness to review and/or approve a plan of work for exploitation under the United Nations Convention on the Laws of the Sea (UNCLOS); the Company’s ability to obtain exploitation contracts or approved plans of work for exploitation for its areas in the Clarion Clipperton Zone; regulatory uncertainties and the impact of government regulation and political instability on the Company’s resource activities; changes to any of the laws, rules, regulations or policies to which the Company is subject, including the terms of the final Mining Code, if any, adopted by ISA and the potential timing thereof; the impact of extensive and costly environmental requirements on the Company’s operations; environmental liabilities; the impact of polymetallic nodule collection on biodiversity in the Clarion Clipperton Zone and recovery rates of impacted ecosystems; the Company’s ability to develop minerals in sufficient grade or quantities to justify commercial operations; the lack of development of seafloor polymetallic nodule deposit; the Company’s ability to successfully enter into binding agreements with Allseas Group S.A. and other parties in which it is in discussions, if any; uncertainty in the estimates for mineral resource calculations from certain contract areas and for the grade and quality of polymetallic nodule deposits; risks associated with natural hazards; uncertainty with respect to the specialized treatment and processing of polymetallic nodules that the Company may recover; risks associated with collective, development and processing operations, including with respect to the development of onshore processing capabilities and capacity and Allseas Group S.A.’s expected development efforts with respect to the Project Zero offshore system; the Company’s dependence on Allseas Group S.A.; fluctuations in transportation costs; fluctuations in metals prices; testing and manufacturing of equipment; risks associated with the Company’s limited operating history, limited cash resources and need for additional financing; risks associated with the Company’s intellectual property; Low Carbon Royalties’ limited operating history and other risks and uncertainties, any of which could cause the Company’s actual results to differ from those contained in the forward-looking statements, that are described in greater detail in the section entitled “Risk Factors” in the Company’s Annual Report on Form 10-K filed with the SEC on March 27, 2023, as updated in our Quarterly Report on Form 10-Q filed with the SEC on August 14, 2023, as well as in other filings the Company may make with the SEC in the future. Any forward-looking statements contained in this press release speak only as of the date hereof, and the Company expressly disclaims any obligation to update any forward-looking statements contained herein, whether because of any new information, future events, changed circumstances or otherwise, except as otherwise required by law.

GlobeNewswire Distribution ID 8952301

Posted on

Philips supports Tampere Heart Hospital in Finland to decarbonize its clinical operations

October 19, 2023

Sustainability roadmap addresses opportunities to reduce carbon emissions in patient throughput, technology use, and use of consumables

Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced the completion of a comprehensive hospital-wide analysis of Tampere Heart Hospital – Tampere University Hospital’s (Finland) environmental sustainability, including a deep assessment of the interventional cardiology space and evaluation of its carbon footprint. The results of the analysis have been translated into a joint action plan that will help Heart Hospital accelerate its decarbonization efforts in line with Finland’s world-leading commitment to reach net zero emissions by 2035.

“Sustainability is an integral part of Tampere Heart Hospital strategy. We are aware that hospitals generate a significant amount of waste daily and consume a lot of energy. We want to contribute to the development of environmental responsibility in healthcare,” said Pasi Lehto CEO and Chief Medical Officer at Heart Hospital.

“We want to ascertain where we are now and how we can further accelerate our transition towards net zero,” said Aki Haukilahti, CFO at Tampere Heart Hospital. “Our long-standing relationship with Philips and their industry leadership in driving sustainable healthcare made them a natural partner to help audit our emissions and develop a roadmap for the future.”

Part of an existing 15-year strategic managed services agreement between Heart Hospital and Philips, the analysis involved a detailed lifecycle assessment of the hospital’s medical equipment, supply chain, and clinical operations. The analysis provided a baseline carbon footprint for Tampere Heart Hospital’s interventional cardiology service and facilitated the identification of opportunities to enhance patient throughput and equipment utilization to reduce future emissions. Top findings included optimization of the hospital’s patient care pathways to improve efficiency and materials use, and opportunities for reducing inbound airfreight, reducing waste and improving waste separation.

“At Philips, we are committed to driving systemic change towards more sustainable and equitable patient care. Through our healthcare technology and expertise, we can help healthcare providers to support their patients with as little impact on the environment as possible,” said Robert Metzke, Global Head of Sustainability at Philips. “This valuable and informative analysis with Tampere Heart Hospital, a pioneering and leading global cardiac care provider, will help achieve our shared goal of taking care of patients and the planet at the same time.”

In addition to a detailed analysis of carbon emissions associated with the hospital’s medical equipment and supply chain, Philips’ analysis of the hospital’s current emissions also encompasses clinical operations in key patient care pathways.

This sustainability program with Tampere Heart Hospital follows similar analyses conducted by Philips earlier in 2023 at Vanderbilt University Medical Center (Nashville, USA) and the private biomedical research and clinical care provider Champalimaud Foundation (Lisbon, Portugal), aimed at reducing the carbon footprint of their diagnostic imaging.

Globally, healthcare systems have a significant climate footprint and make a major contribution to the climate crisis [1]. Building on decades of experience reducing energy consumption, waste, and materials and substance usage, Philips has operated globally carbon-neutral since 2020, embedding EcoDesign principles and circular business models into its innovation processes and ways of working. The company offers a range of health technologies and innovations that help reduce healthcare providers’ impact on the environment. For example, its Philips Spectral CT 7500 uses 62.5% less energy [2], and the Philips MR – Ingenia Ambition 1.5T, which uses a breakthrough design where the magnetic components are completely sealed and only need seven liters of helium over its lifetime compared to roughly 1,500 liters with other Philips systems [3]. Additionally, with Philips MR SmartSpeed, the Ingenia Ambition 1.5T uses up to 53% less power per patient scan [3].

Read more here on how Philips is partnering with hospitals around the world to drive sustainable healthcare.

[1] https://noharm-global.org/sites/default/files/documents-files/5961/HealthCaresClimateFootprint_092319.pdf
[2] When compared to an equivalent CT model of one of the industry leaders
[3] Applicable to Ambition S. Philips SmartSpeed power consumption versus Philips SENSE based scanning. Based on COCIR and in-house simulated environment. Results can vary based on site conditions.

For further information, please contact:

Joost Maltha
Philips Global Press Office
Tel: +31 6 10 55 8116
Email: joost.maltha@philips.com

About Royal Philips

Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people’s health and well-being through meaningful innovation. Philips’ patient- and people-centric innovation leverages advanced technology and deep clinical and consumer insights to deliver personal health solutions for consumers and professional health solutions for healthcare providers and their patients in the hospital and the home. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, ultrasound, image-guided therapy, monitoring and enterprise informatics, as well as in personal health. Philips generated 2022 sales of EUR 17.8 billion and employs approximately 71,500 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter.

Attachment

GlobeNewswire Distribution ID 1000864876

Posted on

Steel decarbonisation to redefine supply chains by 2050

Wood Mackenzie report says new metallic hubs will emerge as steel industry accelerates carbon abatement efforts

LONDON and HOUSTON and SINGAPORE, Oct. 19, 2023 (GLOBE NEWSWIRE) — According to the latest Horizons report from Wood Mackenzie, the steel industry is set to undergo a significant transformation as decarbonisation efforts accelerate. Titled Metalmorphosis: how decarbonisation is transforming the iron and steel industry the report highlights the emergence of new metallic hubs and the reshaping of steel production and global trade patterns.

Wood Mackenzie’s latest report says electric-arc furnace (EAF) technology, increased use of green feedstock, and evolving carbon policies will play a crucial role in this transformation. Low-carbon intensive EAF production accounts for 28% of global steel output, projected to rise to 50% by 2050. An investment of US$130 billion will be required to achieve this goal.

The shift towards less carbon-intensive steel will drive the demand for greener feedstocks such as DRI (Direct Reduced Iron) and high-grade scrap. Wood Mackenzie predicts that the share of these feedstocks in total metals demand will increase from 36% to 54% by 2050, leading to new production, processing, and trading hubs for low-carbon iron and scrap.

DRI production and trade rise will create investment and revenue generation opportunities across the value chain. Wood Mackenzie forecasts a doubling DRI capacity within 30 years, requiring an estimated US$80 billion investment. This projection does not include potential investments in green hydrogen, smelters for low-grade DRI, pellet hubs, and shipping.

Wood Mackenzie indicates that the location of new green Direct Reduced Iron (DRI) centres will be determined based on their proximity to low-carbon hydrogen production. This is particularly important given the uncertainties surrounding the transportation and storage of traded hydrogen. The Middle East and Australia are well-positioned to take advantage of this opportunity, and the number of projects in these regions is increasing.

Quality will take precedence over quantity as the cost of lower-carbon steel rises. In markets with high carbon prices, importing green DRI to manufacture low-carbon steel using EAFs will become more favourable than importing finished steel from emissions-intensive producers like China and India.

Decarbonising the iron and steel industry, which currently accounts for approximately 8% of global carbon emissions, is a challenging but achievable goal. With the right levels of investment and policy support, this transformation has the potential to redefine trade patterns and the value chain.

Editor’s notes:
Read more information here. To request the report and arrange an interview with the authors, please contact Wood Mackenzie’s media relations team.

About Wood Mackenzie
Wood Mackenzie is the global insight business for renewables, energy and natural resources. Driven by data. Powered by people. In the middle of an energy revolution, businesses and governments need reliable and actionable insight to lead the transition to a sustainable future. That’s why we cover the entire supply chain with unparalleled breadth and depth, backed by over 50 years’ experience in natural resources.

Contacts:
Hla Myat Mon
PR Manager – APAC
hla.myatmon@woodmac.com

GlobeNewswire Distribution ID 1000864826

Posted on

MENACW 2023 เน้นย้ำบทบาทสำคัญของการประชุมฟอรั่มแร่ธาตุแห่งอนาคตในการกำหนดห่วงโซ่คุณค่าของแร่ธาตุที่ยั่งยืนเพื่อการเปลี่ยนผ่านสู่พลังงานสะอาด

กรุงริยาด, ประเทศซาอุดีอาระเบีย, Oct. 19, 2023 (GLOBE NEWSWIRE) — การประชุม The Middle East and North Africa Climate Week (MENACW) 2023 ซึ่งจัดขึ้นในกรุงริยาด เป็นการเน้นย้ำบทบาทสำคัญของการประชุมฟอรั่มแร่ธาตุแห่งอนาคต (Future Minerals Forum – FMF) ในการกำหนดอนาคตของแร่ธาตุ

คณะผู้อภิปรายซึ่งดำเนินรายการโดย Aldo Pennini ผู้อำนวยการฝ่ายกลยุทธ์ โครงการ และเนื้อหาของ FMF พร้อมด้วยบรรดาวิทยากรผู้ทรงเกียรติ ได้แก่ Abdulrahman Al Belushi ผู้ช่วยรองรัฐมนตรีด้านการส่งเสริมการทำเหมืองแร่ของกระทรวงอุตสาหกรรมและแหล่งทรัพยากรแร่, Saud Al Mandil วิศวกรและรองประธานฝ่ายเทคโนโลยี การวิจัยและการพัฒนา และนวัตกรรมที่ Ma’aden, Dr. Thamer Aldaajani ผู้จัดการทั่วไปฝ่ายการวิจัยการทำเหมืองแร่และไฮโดรคาร์บอนที่ King Abdulaziz City for Science and Technology, Ali Al-Mutairi ผู้อำนวยการบริหารที่ FMF, Dr. Abdullah Al-Nabhan ผู้อำนวยการอาวุโสฝ่ายการสำรวจข้อมูลและการสำรวจแร่ที่ Saudi Geological Survey และศาสตราจารย์ Jim Skie ประธานคณะกรรมมาธิการร่วมของหน่วยงานภาครัฐด้านการเปลี่ยนแปลงสภาพภูมิอากาศ

“แร่ธาตุเป็นเสมือนเสาหลักสำคัญในการขับเคลื่อนอุตสาหกรรมและโครงการต่าง ๆ มากมาย” Abdulrahman Al Belushi กล่าว เขากล่าวย้ำถึงความจำเป็นที่ต้องปฏิบัติการอย่างยั่งยืนเพื่อลดผลกระทบต่อสิ่งแวดล้อมให้เหลือน้อยที่สุดและรับประกันว่าชุมชนจะได้รับประโยชน์

Saud Al Mandil เน้นถึงความมุ่งมั่นของ Ma’aden ที่มีต่อความยั่งยืนในภาคส่วนการทำเหมืองแร่ บริษัททุ่มเทในการลดผลกระทบต่อสิ่งแวดล้อมให้เหลือน้อยที่สุดและบริหารจัดการทรัพยากรธรรมชาติอย่างรับผิดชอบ ซึ่งสอดคล้องกับพันธกิจของราชอาณาจักรที่จะปฏิบัติตามความตกลงปารีสว่าด้วยการเปลี่ยนแปลงสภาพภูมิอากาศ

Thamer Aldaajani เน้นย้ำถึงบทบาทสำคัญด้านการวิจัยเพื่อทำความเข้าใจผลกระทบของทรัพยากรแร่ที่มีต่อเศรษฐกิจและสิ่งแวดล้อม และพัฒนาห่วงโซ่มูลค่าให้ดียิ่งขึ้น เขายอมรับถึงความท้าทายที่ภาคส่วนการทำเหมืองแร่ต้องเผชิญในการสร้างสมดุลระหว่างการสกัดแร่ธาตุที่ต้องการและการอนุรักษ์สิ่งแวดล้อม

Ali Al-Mutairi ได้สรุปเกี่ยวกับภารกิจของ FMF โดยระบุว่า “FMF ตั้งเป้าหมายที่จะกำหนดอนาคตของแร่ธาตุในบริบทของการเปลี่ยนผ่านด้านพลังงาน โดยการสนทนาแลกเปลี่ยนความคิดเห็นและการร่วมมือกับผู้มีส่วนได้ส่วนเสียหลายฝ่าย ฟอรั่มนี้ทำหน้าที่เป็นเวทีระดับนานาชาติที่เปิดโอกาสให้องค์กรต่าง ๆ เข้ามามีส่วนร่วมในภาคส่วนการทำเหมืองแร่ เพื่อสำรวจโอกาสความเป็นไปได้ในภูมิภาคที่อุดมไปด้วยแร่ธาตุ ตั้งแต่แอฟริกาไปจนถึงเอเชียตะวันตกและเอเชียตอนกลาง”

Abdullah Al-Nabhan บรรยายอย่างละเอียดถึงลักษณะเฉพาะทางธรณีวิทยาของ Arabian Shield โดยเน้นทรัพยากรแร่ที่มีอย่างอุดมสมบูรณ์ซึ่งจำเป็นต่อการเปลี่ยนผ่านสู่พลังงานสีเขียว ในขณะเดียวกัน Professor Jim Skea ได้ประกาศว่านับเป็นครั้งแรกที่ IPCC จะผนวกรวมบทบาทของแร่ธาตุในการเปลี่ยนผ่านด้านพลังงานเข้าเป็นส่วนหนึ่งของรายงานฉบับถัดไปซึ่งครอบคลุมระยะเวลาหลายปี

การประชุม FMF ครั้งที่สามภายใต้การอุปถัมภ์ของ King Salman bin Abdulaziz ผู้อารักขามัสยิดศักดิ์สิทธิ์ทั้งสอง จะจัดขึ้นในวันที่ 9-11 มกราคม 2024 ณ ศูนย์ประชุม King Abdulaziz International Conference Center ในกรุงริยาด

ดูรูปภาพประกอบการแถลงข่าวนี้ได้ที่ https://www.globenewswire.com/NewsRoom/AttachmentNg/c7249c16-1580-4825-bd81-b2946880f9f4

Omar Shereen
มือถือ: +966 50 663 0489
อีเมล: Omar.shereen@fleishman.com

GlobeNewswire Distribution ID 1000864807

Posted on

BlueCat recognized as a leader and outperformer in 2023 GigaOm Radar Report for DDI

BlueCat earns accolade for the second straight year

TORONTO, Oct. 18, 2023 (GLOBE NEWSWIRE) — BlueCat Networks, a leading provider of mission-critical network and cloud infrastructure software for reliable and secure DNS, DHCP, and IP address management (collectively known as DDI), today announced that it has been recognized for the second straight year as a leader and outperformer in the 2023 GigaOm Radar Report for DDI.

DDI provides the core services that route traffic and enable network communications. The report highlights key DDI vendors and equips IT decision-makers with the information needed to select the best fit for their business and use case requirements.

GigaOm describes BlueCat Integrity as a purpose-built enterprise DDI platform for centralizing control of core DDI services and gaining insight into enterprise-wide relationships among devices, users, and IP addresses via a single web-based interface.

“Right-sized from the start, BlueCat Integrity offers deployment flexibility with true pay-as-you-grow linear scalability and safe, secure migrations,” wrote GigaOm analyst Ivan McPhee.

The report also recognized Men&Mice as an outperformer. BlueCat acquired Men&Mice, and its DDI orchestration solution, Micetro, in May 2023. The move extends BlueCat’s mid-market offerings and enhances its core network services portfolio. GigaOm’s recognition of Men&Mice for innovation demonstrates that BlueCat is now even better positioned to offer cutting-edge DDI platforms and solutions for a wider range of enterprises.

“Network teams need dynamic tools that help them simplify management, thwart security threats, and ensure resilience,” said Martin McNealis, Chief Product Officer at BlueCat. ”GigaOm’s analysis highlights how our portfolio delivers on that promise, improving network performance and reducing vulnerabilities for our customers.”

Last year, BlueCat was also recognized in GigaOm’s annual report as a leader, outperformer, and mature play provider of integrated DDI solutions.

To download a complimentary copy of the 2023 GigaOm Radar Report for DDI and review the key criteria for evaluating DDI solutions, visit bluecat.com/gigaom.

About BlueCat
BlueCat is the Adaptive DNS company. The company’s mission is to help organizations deliver reliable and secure network access from any location and any network environment. To do this, BlueCat re-imagined DNS. The result – Adaptive DNS – is a dynamic, open, secure, scalable, and automated DDI management platform that supports the most challenging digital transformation initiatives, like adoption of hybrid cloud and rapid application development. BlueCat’s DDI management platform was recognized as a market leader and outperformer in the 2022 and 2023 GigaOm Radar reports that evaluated all the vendors offering DDI management. The company is headquartered in Toronto and New York and has additional offices throughout the world, including in Germany, Iceland, Japan, Singapore, Serbia, and the United Kingdom. Learn more at bluecat.com.

Contact:
Pierre Hamilton
Senior Manager, Corporate Communications
pr@bluecatnetworks.com

GlobeNewswire Distribution ID 8951581